Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $8.31 and traded as low as $7.53. Seres Therapeutics shares last traded at $7.63, with a volume of 25,619 shares trading hands.
Wall Street Analysts Forecast Growth
MCRB has been the topic of a number of analyst reports. Wall Street Zen cut Seres Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Canaccord Genuity Group restated a “buy” rating and issued a $22.00 price target on shares of Seres Therapeutics in a research note on Friday, March 13th. Finally, Weiss Ratings cut Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Seres Therapeutics currently has a consensus rating of “Hold” and an average price target of $22.00.
Read Our Latest Research Report on Seres Therapeutics
Seres Therapeutics Price Performance
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.36 million.
Institutional Trading of Seres Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after acquiring an additional 1,160 shares during the period. Invesco Ltd. increased its position in Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 3,918 shares during the period. State Street Corp increased its position in Seres Therapeutics by 14.0% in the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock valued at $504,000 after acquiring an additional 4,170 shares during the period. Vontobel Holding Ltd. increased its position in Seres Therapeutics by 4.8% in the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after acquiring an additional 4,723 shares during the period. Finally, Bank of America Corp DE increased its position in Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 5,157 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.
Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.
Featured Stories
- Five stocks we like better than Seres Therapeutics
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
